Christopher J. Halbrook

The paper compares primary and liver PDAC lesions using single-cell transcriptomics to identify MET as a target in pancreatic cancer metastasis.

The paper shows that lower interfacial tension, achieved by surfactant concentration, can overcome the challenges of high viscosity in microfluidic droplet generation using basement membrane extract.

This study identifies mevalonate biosynthesis as a therapeutic target and biomarker for gemcitabine-resistant pancreatic cancer.

This study shows that ATM-deficient pancreatic cancers reprogram the tumor microenvironment via TGF-β-driven myCAF enrichment, and targeting this stromal axis with chemotherapy improves therapeutic efficacy.

This study shows that pancreatic cancer cells in a nutrient-stressed tumor microenvironment develop drug tolerance, and identifies BCL-XL inhibition as a potential therapeutic strategy.

This study identifies NDRG1 as a DNA repair protein that links pancreatic cancer stroma to chemoresistance by enhancing DNA damage repair through R-loop resolution.

This study shows that G6PD deficiency accelerates pancreatic acinar-to-ductal metaplasia by enhancing NADPH production for ROS management, highlighting a metabolic role in early tumorigenesis.

This study shows that purine metabolism affects DNA repair and therapy resistance in glioblastoma, suggesting that targeting purine synthesis could improve treatment outcomes.